U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Britain Courts Anthropic Amid US Defense Department Dispute 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company’s second quarter 2017 financial results will be released on Tuesday, August 8, 2017. Company management will host a conference call on Tuesday, August 8, 2017 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. The conference call can be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and refer to conference ID 63329558. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Calithera’s website for 30 days.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in Phase 1/2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is being developed in collaboration with Incyte Corporation and is currently in a Phase 1 clinical trial. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
SOURCE: Calithera Biosciences, Incorporated
CONTACT: Jennifer McNealey [email protected] 650-870-1071
